Decoy’s development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer’s extensive scientific knowledge...
SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker,...
Agenda Focuses on Balancing Patient Access and Net Revenue Optimization Keynote Speaker Bill Roth Joins Industry Veterans, Practitioners, and Technologists...
WASHINGTON, April 15, 2025 /PRNewswire/ -- June 4-7, 2025 – Keystone Symposia will host a timely meeting, "Vaccinology: Horizons Across Disease,...
RAHWAY, N.J., April 14, 2025 /PRNewswire/ -- The Merck Manuals is pleased to announce its collaboration with Microsoft to integrate...
Clinically-Inspired Supplement PrimeBiome Gains Momentum in 2025 as Consumers Report Radiant Skin, Improved Gut Health, and Healthy Weight Management—All Backed...
TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- The Ontario Health Coalition is raising concerns about the sharp increase in people...
Mario Danek Appointed President and CEO; James Watson Joins as COO, Francesca Lanuza Appointed Director of Regulatory Affairs, and Dr....
Congress will take place April 21-24, 2025, in Washington, D.C.COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX)...
Highlights will include data from non-clinical and real-world patient useBOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a...
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting...
CHICAGO, April 10, 2025 /PRNewswire/ -- Home to some of the nation's most renowned hospitals and healthcare research centers, Northern...
Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s genetically engineered...
Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infectionsStudy...
HELSINKI and NAPLES, Italy, April 09, 2025 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), an immunotherapy company developing novel, adaptable...
Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine...
HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing...
Burlington, Ontario--(Newsfile Corp. - April 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotech...
Montreal, Quebec--(Newsfile Corp. - April 8, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"),...
EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome...